Ikena Oncology
Ikena Oncology is dedicated to redefining targeted oncology therapies with a mission to find cures for every cancer patient. They develop biomarker-driven targeted cancer therapies, focusing on understanding cancer mechanisms and tailoring treatments to specific patient populations. Their approach involves analyzing cancer-driving targets, identifying patients with specific mutations, and employing tailored combination therapies to target key drivers of cancer progression. Their pipeline includes novel therapies such as IK-595, a MEK-RAF molecular glue, and IK-930, a TEAD inhibitor, among others. The company emphasizes innovation, scientific research, and a patient-centric approach to cancer treatment.
Industries
Nr. of Employees
medium (51-250)
Ikena Oncology
645 Summer Street, Suite 101, Boston, MA 02210
Patents
Products
IK-595
Oral small-molecule candidate described as a MEK–RAF complex inhibitor (molecular-glue mechanism) designed to more completely inhibit RAS/MAPK signaling in RAS- or RAF-altered solid tumors; developed for monotherapy and combination use with a pharmacokinetic profile suited to oral dosing.
IK-930
Small-molecule inhibitor targeting TEAD transcriptional activity aimed at TEAD/YAP/TAZ-dependent cancers; evaluated as monotherapy and in combinations to attenuate drug-tolerant cell proliferation.
IK-175
Oral AHR (aryl hydrocarbon receptor) pathway inhibitor investigated as monotherapy and in combination with PD-1/PD-L1 inhibitors for AHR-enriched tumor indications such as urothelial carcinoma.
IK-007
Program targeting EP4 signaling intended for combination with checkpoint inhibitors for indications such as microsatellite-stable colorectal cancer (MSS-CRC).
IK-412
Program targeting kynurenine pathway biology for evaluation across multiple solid tumor indications.
IK-595
Oral small-molecule candidate described as a MEK–RAF complex inhibitor (molecular-glue mechanism) designed to more completely inhibit RAS/MAPK signaling in RAS- or RAF-altered solid tumors; developed for monotherapy and combination use with a pharmacokinetic profile suited to oral dosing.
IK-930
Small-molecule inhibitor targeting TEAD transcriptional activity aimed at TEAD/YAP/TAZ-dependent cancers; evaluated as monotherapy and in combinations to attenuate drug-tolerant cell proliferation.
IK-175
Oral AHR (aryl hydrocarbon receptor) pathway inhibitor investigated as monotherapy and in combination with PD-1/PD-L1 inhibitors for AHR-enriched tumor indications such as urothelial carcinoma.
IK-007
Program targeting EP4 signaling intended for combination with checkpoint inhibitors for indications such as microsatellite-stable colorectal cancer (MSS-CRC).
IK-412
Program targeting kynurenine pathway biology for evaluation across multiple solid tumor indications.
Services
Engagement with external partners for co-development, licensing, and collaborative research to advance targeted oncology programs.
Clinical development support including Phase 1 trial design and clinical operations for oncology candidates.
Development of assays to identify patients with specific molecular alterations for inclusion in targeted therapy trials.
Engagement with external partners for co-development, licensing, and collaborative research to advance targeted oncology programs.
Clinical development support including Phase 1 trial design and clinical operations for oncology candidates.
Development of assays to identify patients with specific molecular alterations for inclusion in targeted therapy trials.
Expertise Areas
- Targeted oncology drug discovery
- Translational research and biomarker development
- Small-molecule medicinal chemistry
- Structure-based drug design
Key Technologies
- Molecular-glue small-molecule therapeutics
- Structure-based design
- Medicinal chemistry
- Computational chemistry
News & Updates
Final results from a Phase 1b study of IK-175, an oral AHR inhibitor, used as monotherapy and in combination with Nivolumab in patients with resistant or refractory urothelial carcinoma.
Results from a first-in-human study of IK-595, a molecular glue targeting MEK and RAF, in patients with RAS or RAF altered advanced solid tumors.
An article discussing the anti-tumor activity of IK-595 in RAS/MAPK pathway-altered cancers.
A study on IK-595's ability to target the MEK-RAF complex and overcome resistance mechanisms in RAS/RAF altered cancers.
Final results from a Phase 1b study of IK-175, an oral AHR inhibitor, used as monotherapy and in combination with Nivolumab in patients with resistant or refractory urothelial carcinoma.
Results from a first-in-human study of IK-595, a molecular glue targeting MEK and RAF, in patients with RAS or RAF altered advanced solid tumors.
An article discussing the anti-tumor activity of IK-595 in RAS/MAPK pathway-altered cancers.
A study on IK-595's ability to target the MEK-RAF complex and overcome resistance mechanisms in RAS/RAF altered cancers.